Mercado global de encapsulamento de células vivas eletrostáticas – Tendências do setor e previsão para 2030

 Análise e tamanho do mercado de encapsulamento eletrostático de células vivas

A crescente procura de novos sistemas de distribuição de medicamentos para o tratamento de doenças tem impulsionado o mercado e prevê-se que seja um potencial impulsionador para o mercado de encapsulação eletrostática de células vivas de 2023 a 2030. Os crescentes investimentos público-privados para apoiar o desenvolvimento de novos produtos estão também a contribuir para o crescimento do mercado-alvo. Vários avanços tecnológicos, a crescente consciencialização pública sobre o papel clínico das células encapsuladas na gestão de doenças, o aumento das atividades de investigação para estabelecer a eficácia clínica das tecnologias de encapsulação celular e a crescente consciencialização pública sobre o papel clínico das células encapsuladas estão a aumentar o encapsulamento eletrostático de células vivas.

A Data Bridge Market Research analisa que o mercado de encapsulamento eletrostático de células vivas, que é de 296,69 milhões de dólares em 2022, deverá atingir os 409,18 milhões de dólares até 2030, com um CAGR de 4,1% durante o período de previsão de 2023 a 2030. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análise especializada aprofundada, epidemiologia de doentes, análise de pipeline, análise de preços e enquadramento regulamentar.

Âmbito e segmentação do mercado de encapsulamento eletrostático de células vivas  

Market Definition

Live cell encapsulation has long been proposed as a solution to many therapeutic problems in modern medicine. Cell encapsulation technology is used to immobilise cells within biocompatible and semipermeable membranes. Encapsulation of cells, rather than therapeutic products, is used to allow the delivery of molecules of interest for a longer time period because cells release these molecules of interest continuously. Furthermore, cells can be engineered to express the desired protein in vivo without modifying the host's genome. Cell encapsulation has a significant advantage over protein encapsulation because it allows for the sustained and controlled delivery of therapeutic molecules at a constant rate, resulting in higher physiological concentrations.

Global Electrostatic Live Cell Encapsulation Market Dynamics

Drivers

• Rising public-private investments

Growing public-private investments in product development are a key driver of the electrostatic live cell encapsulation market's expansion. Austrianova, a global company with offices in Singapore and Thailand, plans to launch a novel and proprietary technology for encapsulating living mammalian (Cell-in-a-Box) and bacterial (Bac-in-a-Box) cells in July 2021 using cellulose sulfate-based materials. As a result of this investment, Real Tech invested in a fund as a strategic partner for Austrianova's entry into the Japanese market. Such initiatives contribute to market growth during the forecast period.

Opportunities

• Increasing research programs

The growing number of research programmes aimed at proving the clinical efficacy of the cell encapsulation process is driving market growth. According to a study titled "Porous microcapsules encapsulating cells generated by microfluidic electrospray technology for diabetes treatment" published in the NGP Asia Material in May 2022, blood glucose levels and body weights improved with live cell porous microcapsules encasing cells. These characteristics indicate that porous microcapsules encasing cells are effective in the treatment of diabetes, and researchers believe that this method will be widely used in the clinic due to its superior capabilities. As a result, the efficacy of live cell encapsulation therapy in diabetes treatment is a promising approach that is expected to drive market growth.

Restraints/Challenges

• High cost of product

High product manufacturing costs and a scarcity of high-quality raw materials on the market will impede the growth of the electrostatic live cell encapsulation market from 2023 to 2030. The widespread use of alternative therapies will challenge the market's growth during the forecast period.

This electrostatic live cell encapsulation market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the electrostatic live cell encapsulation market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2022, Sernova Corp. and Evotec SE announced a global strategic partnership to develop a best-in-class cell therapy treatment for people with insulin-dependent diabetes. The two companies will collaborate and leverage their respective technologies and scientific expertise to create an implantable iPSC-based (induced pluripotent stem cells) beta cell replacement therapy that will provide an unlimited insulin-producing cell source to patients with insulin-dependent diabetes.
• In 2022, PharmaCyte Biotech, Inc. announced that it had successfully completed a 24-month product stability study mandated by the US Food and Drug Administration (FDA) for its clinical trial product candidate, CypCaps. The significance of this timepoint is that CypCaps has now demonstrated a shelf life of at least 24 months when stored at room temperature.

Global Electrostatic Live Cell Encapsulation Market Scope

The electrostatic live cell encapsulation market is segmented on the basis of polymer type and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Polymer Type

• Alginate
• HEMA-MMA (Hydroxyethyl Methacrylate-Methyl Methacrylate)
• Chitosan
• Siliceous Encapsulates
• Cellulose Sulfate
• PAN-PVC (Poly Acrylonitrile Vinyl Chloride)
• Others

Application

• Drug Delivery
• Regenerative Medicine
• Cell Transplantation
• Probiotics
• Research

Electrostatic Live Cell Encapsulation Market Regional Analysis/Insights

The electrostatic live cell encapsulation market is analyzed and market size insights and trends are provided by country, polymer type and application as referenced above.

The countries covered in the electrostatic live cell encapsulation market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the electrostatic live cell encapsulation market because of the region's well-developed healthcare infrastructure and favourable reimbursement policies.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the strict rising research and development activities and increase in government initiatives to enhance health care in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The electrostatic live cell encapsulation market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for electrostatic live cell encapsulation market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the electrostatic live cell encapsulation market. The data is available for historic period 2011-2021.

Competitive Landscape and Electrostatic Live Cell Encapsulation Market Share Analysis

The electrostatic live cell encapsulation market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to electrostatic live cell encapsulation market.

Some of the major players operating in the electrostatic live cell encapsulation market are:

• ViaCyte, Inc.
• MIKROCAPS (Eslovénia)
• (EUA)
• Sernova Corp (Canadá)
• Blacktrace Holdings Limited (Reino Unido)
• Merck KGaA (Alemanha)
• BÜCHI Labortechnik AG (Suíça)
• PharmaCyte Biotech (EUA)
• Living Cell Technologies Limited (Nova Zelândia)
• Sigilon Therapeutics, Inc.
• Encapsis, LLC (EUA)
• Neurotech LLC (EUA)
• (Israel)
• Beta-O2 Technologies Ltd (Israel)
• DuPont (EUA)
• Austrianova (Índia)

SKU-56869